Cancer 'cure' in mice to be tested in humans

June 30, 2008

WINSTON-SALEM, N.C. - Scientists at Wake Forest University Baptist Medical Center are about to embark on a human trial to test whether a new cancer treatment will be as effective at eradicating cancer in humans as it has proven to be in mice.

The treatment will involve transfusing specific white blood cells, called granulocytes, from select donors, into patients with advanced forms of cancer. A similar treatment using white blood cells from cancer-resistant mice has previously been highly successful, curing 100 percent of lab mice afflicted with advanced malignancies.

Zheng Cui, Ph.D., lead researcher and associate professor of pathology, will be announcing the study June 28 at the Understanding Aging conference in Los Angeles.

The study, given the go-ahead by the U.S. Food and Drug Administration, will involve treating human cancer patients with white blood cells from healthy young people whose immune systems produce cells with high levels of cancer-fighting activity.

The basis of the study is the scientists' discovery, published five years ago, of a cancer-resistant mouse and their subsequent finding that white blood cells from that mouse and its offspring cured advanced cancers in ordinary laboratory mice. They have since identified similar cancer-killing activity in the white blood cells of some healthy humans.

"In mice, we've been able to eradicate even highly aggressive forms of malignancy with extremely large tumors," Cui said. "Hopefully, we will see the same results in humans. Our laboratory studies indicate that this cancer-fighting ability is even stronger in healthy humans."

The team has tested human cancer-fighting cells from healthy donors against human cervical, prostate and breast cancer cells in the laboratory - with surprisingly good results. The scientists say the anti-tumor response primarily involves granulocytes of the innate immune system, a system known for fighting off infections.

Granulocytes are the most abundant type of white blood cells and can account for as much as 60 percent of total circulating white blood cells in healthy humans. Donors can give granulocytes specifically without losing other components of blood through a process called apheresis that separates granulocytes and returns other blood components back to donors.

In a small study of human volunteers, the scientists found that cancer-killing activity in the granulocytes was highest in people under age 50. They also found that this activity can be lowered by factors such as winter or emotional stress. They said the key to the success for the new therapy is to transfuse sufficient granulocytes from healthy donors while their cancer-killing activities are at their peak level.

For the upcoming study, the researchers are currently recruiting 500 local potential donors who are 50 years old or younger and in good health to have their blood tested. Of those, 100 volunteers with high cancer-killing activity will be asked to donate white blood cells for the study. Cell recipients will include 22 cancer patients who have solid tumors that either didn't respond originally, or no longer respond, to conventional therapies. The study will cost $100,000 per patient receiving therapy, and for many patients (those living in 22 states, including North Carolina) the costs may be covered by their insurance company. There is no cost to donate blood. For general information about insurance coverage of clinical trials, go to the American Cancer Society's web site at www.cancer.org/docroot/ETO/content/ETO_6_2x_State_Laws_Regarding_Clinical_Trials.asp.)

For more information about qualifications for donors and participants, go to www.wfubmc.edu/LIFT (Web site will be available the evening of 6/27.) Cancer-killing ability in these cells is highest during the summer, so researchers are hoping to find volunteers who can afford the therapy quickly.

"If the study is effective, it would be another arrow in the quiver of treatments aimed at cancer," said Mark Willingham, M.D., a co-researcher and professor of pathology. "It is based on 10 years of work since the cancer-resistant mouse was first discovered."

Volunteers who are selected as donors - based on the observed potential cancer-fighting activity of their white cells - will complete the apheresis, a two- to three-hour process similar to platelet donation, to collect their granulocytes. The cancer patients will then receive the granulocytes through a transfusion - a safe process that has been used for more than 30 years. Normally, the treatment is used for patients who have antibiotic-resistant infectious diseases. The treatment will be given for three to four consecutive days on an outpatient basis. Up to three donors may be necessary to collect enough blood product for one study participant.

"The difference between our study and the traditional white cell therapy is that we're selecting the healthy donors based on the cancer-killing ability of their white blood cells," said Cui. The scientists are calling the therapy Leukocyte InFusion Therapy (LIFT).

The goal of the phase II study is to determine whether patients can tolerate a sufficient amount of transfused granulocytes for the treatment. Participants will be monitored on a regular basis, and after three months scientists will evaluate whether the treatment results in clear clinical benefits for the patients. If this phase of the study is successful, scientists will expand the study to determine if the treatment is best suited to certain types of cancer.

Wake Forest University Baptist Medical Center

Granulocytes: Production, Types and Roles in Disease (Cell Biology Research Progress)
by Hisao Abukara (Author), Michi Jumonji (Editor)

This book examines the latest research developments in the study of the production, types and roles in disease of granulocytes. Topics include the regulation of granulocyte differentiation by microRNA and transcription factors; chemotactic assay of human neutrophils and eosinophils; basophilic granulocytes; and the role of granulocytes on the onset of tissue-destructive diseases.

Granulocyte-macrophage: Webster's Timeline History, 1973 - 2007
by Icon Group International (Author)

Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Granulocyte-macrophage," including when used in literature (e.g. all authors that might have Granulocyte-macrophage in their name). As such, this book represents the largest compilation of timeline events associated with Granulocyte-macrophage when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop...

Granulocyte-Colony: Webster's Timeline History, 1984 - 2007
by Icon Group International (Author)

Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Granulocyte-Colony," including when used in literature (e.g. all authors that might have Granulocyte-Colony in their name). As such, this book represents the largest compilation of timeline events associated with Granulocyte-Colony when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the...

Granulocyte Responses to Cytokines (Immunology)
by R. G. Coffey (Author)

This volume explores the basic physiological functions of granulocytes, their modification by cytokines, and the clinical experience with cytokines - discussing the specific responses of neutrophils, eosinophils, basophils, and mast cells to individual cytokines.;Written by more than 60 experts from all over the world, Granulocyte Responses to Cytokines ...: examines the responses of granulocytes and mast cells to hormones, chemotactic peptides, and phorbol esters; details cytokine effects on morphology, micration, adhesion, phagocytosis, degranulation, and cytotoxicity against tumour cells and pathogens; covers cyclic nucleotide, protein kinases, G proteins, lipoxygenase, and leukotrienes in the regulation of granulocyte functions; indicates caution in the use of cytokine therapy for...

Blood Cell Biochemistry, Volume 3: Lymphocytes and Granulocytes (v. 3)
by J. Robin Harris (Editor)

The granulocyte: Function and clinical utilization (Progress in clinical and biological research)
by A.R. Liss (Publisher)

Granulocyte Serology: A Clinical and Laboratory Guide
by Jeffrey McCullough (Author), Cynthia Press (Author), Mary Clay (Author), William Kline (Author)

Handbook of Granulocytes: Classification, Toxic Materials Produced and Pathology (Human Anatomy and Physiology)
by Reuben Hagg (Editor), Soren Kohlund (Editor)

Granulocytes are a category of white blood cells characterised by the presence of granules in their cytoplasm. This book examines the characteristics of eosinophil granulocytes, its biological functions, its role in inflammation and its clinical significance in children. This book also reviews the role of granulocytes on the onset of tissue-destructive diseases when exposed to stress. In addition to the cases of disease, some physiological phenomena are also responsible for the stress-induced granulocytosis. Thus this book will also expands upon the role of granulocytes associated with various diseases and some physiological responses. Other topics discussed in this book include the role of basophil, the minute group of granulocyte, in tropical infections and in immune regulations;...

Basophil Granulocytes (Cell Biology Research Progress)
by Paul K. Vellis (Editor)

This book examines the latest research developments in the field of basophil granulocytes, sometimes referred to as basophils, which are the least common of the granulocytes, representing about 0.01 per cent to 0.3 per cent of circulating white blood cells. The name comes from the fact that these leucocytes are basophilic, i.e., they are susceptible to staining by base dyes, as shown in the picture. Basophils contain large cytoplasmic granules which obscure the cell nucleus under the microscope. However, when unstained, the nucleus is visible and it usually has 2 lobes. The mast cell, a cell in tissues, has many similar characteristics.

Granulocyte: Webster's Timeline History, 1878 - 2000
by Icon Group International (Author)

Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Granulocyte," including when used in literature (e.g. all authors that might have Granulocyte in their name). As such, this book represents the largest compilation of timeline events associated with Granulocyte when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...